Controlled release technology has evolved significantly over time. Early controlled release systems relied on microencapsulation and diffusion-based release, while more advanced modern systems utilize nanotechnology, MEMS, and transdermal patches to achieve targeted delivery. Controlled release provides opportunities for life cycle management and competitive advantages over immediate release products. The global market for drug delivery products is large and growing, with the oral route being the most common. Emerging technologies like 3D printing and smart materials are pushing the field in new directions for the future.
This document discusses driving innovation in the mature packaged gases market. It outlines six key strategic initiatives: 1) embedding technology in business strategy and linking it to market segmentation, 2) demanding differentiated offerings, 3) using an integrated cross-functional process, 4) driving voice of the customer input at all stages, 5) managing the gate process for moving innovations to commercialization aggressively, and 6) using tools and metrics to support cultural change toward innovation. The initiatives aim to shift from a supply chain focus to high value offerings in order to drive profit growth through differentiation rather than just cost reduction.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
Release Funds from Working Capital with N&Gmturnersamuels
This document discusses working capital optimisation from N&G, a consulting firm specializing in working capital and supply chain optimization. It provides an overview of N&G's experience, clients, methodology, and philosophy. N&G helps companies optimize working capital through analyses that identify opportunities to improve processes influencing inventory, receivables, and payables. This can free up substantial capital that can then be reinvested or returned to shareholders.
Chemir Analytical Services provides analytical testing services for various industries. It has over 50 years of experience solving problems for nearly 7,000 clients worldwide through techniques like deformulation, materials identification, failure analysis, and litigation support. The document outlines Chemir's capabilities and quality standards for analytical testing and highlights how it has assisted clients in industries like food and beverage, pharmaceuticals, plastics, and medical devices.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
This document provides an overview of management consultancy as an industry and profession. It discusses the history and structure of the industry, profiles of major consulting firms, the largest markets, and professional and ethical standards. The future of the industry is seen as promising with continued growth expected as clients increasingly recognize the value of external advice and complete business solutions that integrate technology. The spectrum of management consultancy has broadened over time and now encompasses a wide range of organizations and practitioners.
The document describes research on developing a framework to assess organizational innovation capability. It involved analyzing literature to identify innovation capabilities, developing a model (ICMM) to assess capabilities, and refining the model using topic modeling and case studies. The topic modeling provided insights into capability themes and interrelationships. Case studies applied the model and identified strengths, weaknesses, and opportunities for different organizations. Participants found the approach useful for discussion, prioritizing improvement efforts, and gaining commitment to those efforts.
The document introduces Jeremy Gilbert and outlines his experience leading innovation and business development across multiple startups and large companies. It highlights Gilbert's expertise in product strategy, software engineering, healthcare markets, and successfully taking new innovations from concept to commercialization over a 15-year career spanning founding startups and consulting at McKinsey. The summary provides an overview of Gilbert's relevant qualifications and experiences in a concise manner.
This document discusses driving innovation in the mature packaged gases market. It outlines six key strategic initiatives: 1) embedding technology in business strategy and linking it to market segmentation, 2) demanding differentiated offerings, 3) using an integrated cross-functional process, 4) driving voice of the customer input at all stages, 5) managing the gate process for moving innovations to commercialization aggressively, and 6) using tools and metrics to support cultural change toward innovation. The initiatives aim to shift from a supply chain focus to high value offerings in order to drive profit growth through differentiation rather than just cost reduction.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
Release Funds from Working Capital with N&Gmturnersamuels
This document discusses working capital optimisation from N&G, a consulting firm specializing in working capital and supply chain optimization. It provides an overview of N&G's experience, clients, methodology, and philosophy. N&G helps companies optimize working capital through analyses that identify opportunities to improve processes influencing inventory, receivables, and payables. This can free up substantial capital that can then be reinvested or returned to shareholders.
Chemir Analytical Services provides analytical testing services for various industries. It has over 50 years of experience solving problems for nearly 7,000 clients worldwide through techniques like deformulation, materials identification, failure analysis, and litigation support. The document outlines Chemir's capabilities and quality standards for analytical testing and highlights how it has assisted clients in industries like food and beverage, pharmaceuticals, plastics, and medical devices.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
This document provides an overview of management consultancy as an industry and profession. It discusses the history and structure of the industry, profiles of major consulting firms, the largest markets, and professional and ethical standards. The future of the industry is seen as promising with continued growth expected as clients increasingly recognize the value of external advice and complete business solutions that integrate technology. The spectrum of management consultancy has broadened over time and now encompasses a wide range of organizations and practitioners.
The document describes research on developing a framework to assess organizational innovation capability. It involved analyzing literature to identify innovation capabilities, developing a model (ICMM) to assess capabilities, and refining the model using topic modeling and case studies. The topic modeling provided insights into capability themes and interrelationships. Case studies applied the model and identified strengths, weaknesses, and opportunities for different organizations. Participants found the approach useful for discussion, prioritizing improvement efforts, and gaining commitment to those efforts.
The document introduces Jeremy Gilbert and outlines his experience leading innovation and business development across multiple startups and large companies. It highlights Gilbert's expertise in product strategy, software engineering, healthcare markets, and successfully taking new innovations from concept to commercialization over a 15-year career spanning founding startups and consulting at McKinsey. The summary provides an overview of Gilbert's relevant qualifications and experiences in a concise manner.
This document provides an introduction to DROMEDA, a consulting firm that offers a variety of operations improvement services to food industry clients. DROMEDA's approach is practical, systematic, detailed, and focused on ensuring early return on investment and cost savings for clients. The document outlines DROMEDA's service offerings and methodology, which involves conducting audits and analyses, identifying issues, developing solutions, implementing plans, and reviewing results. It also provides background on the founder's qualifications and experience in operations leadership and process improvement.
Siegfried is a global pharmaceutical company with over 130 years of experience in the industry. It has 4 sites in Europe and the US and focuses on developing and manufacturing active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. Siegfried offers services across the value chain from chemical development to production to compliance. It has expertise in over 200 chemical reactions and capabilities including high potency manufacturing, spray drying, and process technologies like microreactor technology. Siegfried maintains high quality and compliance standards with certifications and regulatory documentation for multiple global authorities.
The key challenge is to remain successful. This presentation explains could we remain competitive and successful by imbibing the culture of Customer Focus, Continuous Improvement
Customer satisfaction & business excellence sdm college-4th june 2012Chandramouli Natarajan
The document discusses manufacturing excellence and its link to business excellence. It argues that achieving quality, delivery, and cost (QDC) goals through practices like Just-in-Time, cell manufacturing, and continuous improvement (kaizen) can establish operational excellence and satisfy customers. This operational excellence then provides competitive advantage and leads to business excellence by meeting long-term strategic goals. The document emphasizes that world-class manufacturing principles can be applied universally across industries to sustain excellence through employee involvement across functions.
Newgen's Successful 20 Years at a Glance
http://www.newgensoft.com/
Newgen Software Inc. - Solutions for BPM, ECM, DMS, workflow software and business process automation.
Newgen Software is a leading global vendor/provider of Business Process Management (BPM), Enterprise Content Management (ECM), Customer Communication Management (CCM), Document Management System (DMS), Workflow and Process Automation software. The company has a global footprint of 1300+ installations in over 61 countries with large, mission-critical solutions that have been deployed at the world's leading Banks, Insurance firms, BPO’s, Healthcare Organizations, Government, Telecom Companies & Shared Service Centers.
Fisher Scientific is a leading provider of products and services to scientific researchers around the world. In 2005, Fisher had revenues of $5.6 billion and approximately 19,500 employees worldwide. The company facilitates scientific discovery by supplying researchers with over 600,000 products and services. Fisher aims to make its 350,000 customers more efficient and effective through its integrated supply chain and sales/marketing capabilities.
Siegfried is a leading pharmaceutical development and manufacturing company with facilities around the world. It focuses on active pharmaceutical ingredients, intermediates, and finished dosage forms. Siegfried prides itself on speed, reliability, and flexibility in partnering with customers. It has extensive experience in controlled substances and inhalation drug development and manufacturing. Siegfried is committed to quality, safety, environmental protection, and regulatory compliance.
This document provides a 20-year timeline of Newgen Software Technologies Limited, an Indian software company specializing in business process management, enterprise content management, and customer communication management. Some key events highlighted in the timeline include Newgen launching its first products in 1992, becoming a market leader in workflow and document management systems by the 2000s, acquiring several major customers across industries, and achieving several certifications and awards recognizing its growth. The timeline demonstrates Newgen's evolution from early beginnings to becoming a global leader in its field over 20 years.
Corporate Presentation Ll Focus Ls Mar 2012 V1Murali Apparaju
Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry.
Twice as much in half time - What's about the Quality?Mischa Ramseyer
This Slideshow contains principles and practices to improve quality in software engineering process. First we have to make sure that we implement the right stuff and then we have to make sure that we do it right. Agile Quality Assurance is a practice which in the end leads to performance improvements in the software devleopment process.
NHSIL is the innovation manager for the NHS in London, serving over 1.3 million staff across 54 trusts. It helps inventors overcome funding hurdles and commercialize innovations through services like proof of concept funding and seed funding. NHSIL also helps deepen relationships with trusts and increase revenues, loyalty, and training. It is now moving beyond product innovation to strengthen support for operational performance improvement and service innovation across the NHS to help meet budget cuts of £20 billion by 2014. NHSIL is piloting an online platform to build innovation communities and facilitate greater collaboration around shared healthcare challenges.
ImpelPro is a Mumbai-based supply chain management consulting firm formed a year ago by four partners with over 110 years of combined experience in industries like 3PL, food, retail, and pharmaceuticals. The firm offers end-to-end integrated supply chain solutions including warehouse audits, design and implementation assistance, and change management support to help clients modernize their operations and meet global standards. ImpelPro has already worked with several well-known companies and aims to expand its service offerings and team of experts to further support clients' sustainable growth.
Complementary and alternative medicine (CAM) use is common among patients with psoriasis. CAM modalities include traditional Chinese medicine (TCM), herbal therapies, dietary supplements, climatotherapy, and mind/body interventions. In this review, evidence from clinical trials investigating the efficacy of CAM for psoriasis is reviewed. There is a large amount of evidence from controlled trials that have shown that the combination of TCM with traditional therapies for psoriasis is more efficacious than traditional therapies alone. I have tried to analyze where are we i this therapeutic area.
Controlled Release Oral Drug Delivery System
Controlled drug delivery is one which delivers the drug at a predetermined rate, for locally or systemically, for a specified period of time.
Auto-injectors: choosing the right path | Insight, issue 2Team Consulting Ltd
The auto-injector market is growing rapidly due to a shift towards self-administration of therapies and a need for product differentiation. Auto-injectors provide patients independence and convenience over traditional syringe administration. While auto-injectors offer benefits, pharmaceutical companies face a complex selection process in choosing a development path for their product. Key decisions include whether to develop a new device, use an off-the-shelf option, or license a technology. Proper upfront planning is important to define needs and requirements, assess development options and timelines, and ensure regulatory approval.
Crossject self & safe needle-free auto-injectors sc im & id - partnering of...SCIENTEX
1. Crossject aims to develop self-administered injectable medicines using its needle-free injection technology, ZENEO®, to optimize clinical benefits, patient compliance, and cost-effective health outcomes.
2. Crossject offers co-development of ZENEO® with biologics and vaccine companies, as well as turnkey "SuperGeneric" drug-device combination products for diseases like rheumatoid arthritis, migraine, and anaphylaxis.
3. Validation studies show ZENEO®'s ease of use, safety, and ability to facilitate self-injection, which can improve treatment compliance compared to traditional needles.
Glutahtione is also known as GSH and is made from glutamic acid, cysteine and glycine. It protects the cells of your body from damages inflicted by peroxides and free radicals. Like all antioxidants, Glutathione helps in neutralizing the effect of free radicals making the cells of your body stronger.
The document discusses psoriasis, a chronic skin condition affecting over 125 million people worldwide. Psoriasis causes thickened, red, scaly skin patches that often itch and bleed. It can also cause joint pain and increase risks for other health issues. The document outlines pharmaceutical company efforts to develop new drug treatments for psoriasis, including topical treatments, biologics, and oral medications currently in clinical trials. It emphasizes the need for comprehensive care that coordinates treatment from specialists and considers patients' needs to best manage psoriasis as a chronic condition.
Biosimilars are protein drugs that are similar but not identical to existing biologic products whose patents have expired. They offer potential cost savings compared to innovator biologics but are more complex than traditional generics. Developing biosimilars requires extensive clinical testing to demonstrate similarity due to biologics' sensitivity to manufacturing processes. Regulatory approval pathways for biosimilars are more complex than for generics and involve demonstrating similarity rather than just bioequivalence.
This document provides an introduction to DROMEDA, a consulting firm that offers a variety of operations improvement services to food industry clients. DROMEDA's approach is practical, systematic, detailed, and focused on ensuring early return on investment and cost savings for clients. The document outlines DROMEDA's service offerings and methodology, which involves conducting audits and analyses, identifying issues, developing solutions, implementing plans, and reviewing results. It also provides background on the founder's qualifications and experience in operations leadership and process improvement.
Siegfried is a global pharmaceutical company with over 130 years of experience in the industry. It has 4 sites in Europe and the US and focuses on developing and manufacturing active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. Siegfried offers services across the value chain from chemical development to production to compliance. It has expertise in over 200 chemical reactions and capabilities including high potency manufacturing, spray drying, and process technologies like microreactor technology. Siegfried maintains high quality and compliance standards with certifications and regulatory documentation for multiple global authorities.
The key challenge is to remain successful. This presentation explains could we remain competitive and successful by imbibing the culture of Customer Focus, Continuous Improvement
Customer satisfaction & business excellence sdm college-4th june 2012Chandramouli Natarajan
The document discusses manufacturing excellence and its link to business excellence. It argues that achieving quality, delivery, and cost (QDC) goals through practices like Just-in-Time, cell manufacturing, and continuous improvement (kaizen) can establish operational excellence and satisfy customers. This operational excellence then provides competitive advantage and leads to business excellence by meeting long-term strategic goals. The document emphasizes that world-class manufacturing principles can be applied universally across industries to sustain excellence through employee involvement across functions.
Newgen's Successful 20 Years at a Glance
http://www.newgensoft.com/
Newgen Software Inc. - Solutions for BPM, ECM, DMS, workflow software and business process automation.
Newgen Software is a leading global vendor/provider of Business Process Management (BPM), Enterprise Content Management (ECM), Customer Communication Management (CCM), Document Management System (DMS), Workflow and Process Automation software. The company has a global footprint of 1300+ installations in over 61 countries with large, mission-critical solutions that have been deployed at the world's leading Banks, Insurance firms, BPO’s, Healthcare Organizations, Government, Telecom Companies & Shared Service Centers.
Fisher Scientific is a leading provider of products and services to scientific researchers around the world. In 2005, Fisher had revenues of $5.6 billion and approximately 19,500 employees worldwide. The company facilitates scientific discovery by supplying researchers with over 600,000 products and services. Fisher aims to make its 350,000 customers more efficient and effective through its integrated supply chain and sales/marketing capabilities.
Siegfried is a leading pharmaceutical development and manufacturing company with facilities around the world. It focuses on active pharmaceutical ingredients, intermediates, and finished dosage forms. Siegfried prides itself on speed, reliability, and flexibility in partnering with customers. It has extensive experience in controlled substances and inhalation drug development and manufacturing. Siegfried is committed to quality, safety, environmental protection, and regulatory compliance.
This document provides a 20-year timeline of Newgen Software Technologies Limited, an Indian software company specializing in business process management, enterprise content management, and customer communication management. Some key events highlighted in the timeline include Newgen launching its first products in 1992, becoming a market leader in workflow and document management systems by the 2000s, acquiring several major customers across industries, and achieving several certifications and awards recognizing its growth. The timeline demonstrates Newgen's evolution from early beginnings to becoming a global leader in its field over 20 years.
Corporate Presentation Ll Focus Ls Mar 2012 V1Murali Apparaju
Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry.
Twice as much in half time - What's about the Quality?Mischa Ramseyer
This Slideshow contains principles and practices to improve quality in software engineering process. First we have to make sure that we implement the right stuff and then we have to make sure that we do it right. Agile Quality Assurance is a practice which in the end leads to performance improvements in the software devleopment process.
NHSIL is the innovation manager for the NHS in London, serving over 1.3 million staff across 54 trusts. It helps inventors overcome funding hurdles and commercialize innovations through services like proof of concept funding and seed funding. NHSIL also helps deepen relationships with trusts and increase revenues, loyalty, and training. It is now moving beyond product innovation to strengthen support for operational performance improvement and service innovation across the NHS to help meet budget cuts of £20 billion by 2014. NHSIL is piloting an online platform to build innovation communities and facilitate greater collaboration around shared healthcare challenges.
ImpelPro is a Mumbai-based supply chain management consulting firm formed a year ago by four partners with over 110 years of combined experience in industries like 3PL, food, retail, and pharmaceuticals. The firm offers end-to-end integrated supply chain solutions including warehouse audits, design and implementation assistance, and change management support to help clients modernize their operations and meet global standards. ImpelPro has already worked with several well-known companies and aims to expand its service offerings and team of experts to further support clients' sustainable growth.
Complementary and alternative medicine (CAM) use is common among patients with psoriasis. CAM modalities include traditional Chinese medicine (TCM), herbal therapies, dietary supplements, climatotherapy, and mind/body interventions. In this review, evidence from clinical trials investigating the efficacy of CAM for psoriasis is reviewed. There is a large amount of evidence from controlled trials that have shown that the combination of TCM with traditional therapies for psoriasis is more efficacious than traditional therapies alone. I have tried to analyze where are we i this therapeutic area.
Controlled Release Oral Drug Delivery System
Controlled drug delivery is one which delivers the drug at a predetermined rate, for locally or systemically, for a specified period of time.
Auto-injectors: choosing the right path | Insight, issue 2Team Consulting Ltd
The auto-injector market is growing rapidly due to a shift towards self-administration of therapies and a need for product differentiation. Auto-injectors provide patients independence and convenience over traditional syringe administration. While auto-injectors offer benefits, pharmaceutical companies face a complex selection process in choosing a development path for their product. Key decisions include whether to develop a new device, use an off-the-shelf option, or license a technology. Proper upfront planning is important to define needs and requirements, assess development options and timelines, and ensure regulatory approval.
Crossject self & safe needle-free auto-injectors sc im & id - partnering of...SCIENTEX
1. Crossject aims to develop self-administered injectable medicines using its needle-free injection technology, ZENEO®, to optimize clinical benefits, patient compliance, and cost-effective health outcomes.
2. Crossject offers co-development of ZENEO® with biologics and vaccine companies, as well as turnkey "SuperGeneric" drug-device combination products for diseases like rheumatoid arthritis, migraine, and anaphylaxis.
3. Validation studies show ZENEO®'s ease of use, safety, and ability to facilitate self-injection, which can improve treatment compliance compared to traditional needles.
Glutahtione is also known as GSH and is made from glutamic acid, cysteine and glycine. It protects the cells of your body from damages inflicted by peroxides and free radicals. Like all antioxidants, Glutathione helps in neutralizing the effect of free radicals making the cells of your body stronger.
The document discusses psoriasis, a chronic skin condition affecting over 125 million people worldwide. Psoriasis causes thickened, red, scaly skin patches that often itch and bleed. It can also cause joint pain and increase risks for other health issues. The document outlines pharmaceutical company efforts to develop new drug treatments for psoriasis, including topical treatments, biologics, and oral medications currently in clinical trials. It emphasizes the need for comprehensive care that coordinates treatment from specialists and considers patients' needs to best manage psoriasis as a chronic condition.
Biosimilars are protein drugs that are similar but not identical to existing biologic products whose patents have expired. They offer potential cost savings compared to innovator biologics but are more complex than traditional generics. Developing biosimilars requires extensive clinical testing to demonstrate similarity due to biologics' sensitivity to manufacturing processes. Regulatory approval pathways for biosimilars are more complex than for generics and involve demonstrating similarity rather than just bioequivalence.
“FORMULATION DEVELOPMENT, STATISTICAL OPTIMIZATION AND EVALUATION OF EXTENDED...Dev Chaudhary
This document discusses developing an extended release tablet for an antidepressant drug using a matrix system. It provides background on extended release drug delivery systems and antidepressant drugs. It then discusses advantages and limitations of extended release systems and matrix systems specifically. The literature review section summarizes several previous studies on developing sustained release formulations using wax or hydrophobic polymers as matrix materials for drugs like tramadol, diclofenac, metformin, and theophylline. The document proposes developing an extended release tablet formulation for an antidepressant drug using a wax or hydrophobic polymer matrix system.
Enteric coating of pharmaceutical productsAshish Garg
1) Enteric coating is used to protect drugs from gastric fluid and release them in the intestines. It uses polymers that are insoluble in acid but dissolve in basic pH.
2) Common enteric coating polymers include polymethacrylates, cellulose esters, and polyvinyl derivatives. They require plasticizers to make the coating flexible and prevent premature drug release in acid.
3) Factors like coating temperature, coating method, and storage conditions must be carefully controlled to ensure a uniform coating layer and stable drug release.
Conventional and novel drug delivery system.ZILLE ALI
This document provides an overview of conventional and novel drug delivery systems. It defines drug delivery as administering pharmaceutical compounds to achieve therapeutic effects. Conventional systems like oral, intravenous, and transdermal delivery are described along with their advantages and disadvantages. Novel drug delivery systems aim to improve drug potency, control release rates, increase safety, and target tissues. They provide sustained therapeutic effects by maintaining drug concentrations and reducing dosing frequency. Various novel approaches include targeted, controlled, and modulated release systems using materials like nanoparticles, liposomes, and hydrogels.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document discusses psoriasis, including its epidemiology, pathophysiology, clinical presentations, diagnosis, differential diagnosis, and management. Psoriasis is a chronic, inflammatory skin condition characterized by red scaly plaques. It has a genetic component and can be triggered by various environmental factors. Clinical diagnosis is usually based on appearance of lesions. Topical therapies are first-line treatment for mild-moderate disease, while phototherapy and systemic therapies may be used for more severe cases. Proper management requires a tailored approach based on individual disease characteristics and goals of improving quality of life and long-term disease control.
This document discusses sustained release formulations (SRDFs), which are designed to release medication over an extended period of time after a single dose. It defines various types of modified release dosage forms and outlines techniques used in SRDF development, including drug and dosage form modification. Drug candidates suited for SRDFs include those with desirable solubility and a high therapeutic index. The document also examines factors that govern SRDF design such as a drug's physicochemical properties and stability.
Business Viability of a Lifescience Early-Stage Projectcarlosgabas
How to assess the business opportunity and commercial viability of a scientific project or early-stage technology? How to attract significant specialized investment?
John Pattullo, CEVA Logistics on 'How Supply Chain Innovation Can Drive Custo...eyefortransport
John Pattullo, CEO of CEVA Logistics speaks on 'How Supply Chain Innovation Can Drive Customer Value' at the 7th European 3PL Summit in Brussels, November 25th 2009.
To download all of the slides from the conference for free visit www.3PLsummit.com/eu_2009ppts
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications such as sample preparation, analysis, and data interpretation.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications including sample preparation, sample analysis, and data interpretation.
The document discusses Thermo Scientific's leadership in serving science through analytical instruments, equipment, reagents, software and services. It highlights the company's size and scale, unmatched capabilities, portfolio of leading brands, and mission to make the world healthier, cleaner and safer. Key strengths include global industry leadership, ability to continuously invest in growth opportunities through R&D, and an excellent track record of financial performance. New products are presented for applications like sample preparation, analysis and data interpretation.
This document discusses innovation challenges and knowledge transfer in the digital era. It provides examples of both incremental and radical innovations, as well as disruptive innovations that break market rules. Key factors for innovation are identified as culture, governance, strategy, and process. Culture requires an innovative DNA and qualities like quickness, openness, teamwork, focus, and positivity. Governance involves defining roles for leadership, R&D, and other functions. Strategy requires strategic alignment with the company and flexibility to spin out non-aligned projects. Process involves defining a clear innovation funnel with multiple steps of validation and testing from ideas to implementation. Open innovation and listening to consumer trends and scenarios are also emphasized for driving innovation.
Pfizer at Cowen and Company 28th Annual Health Care Conferencefinance5
This document outlines Pfizer's strategies and priorities moving forward. It discusses (1) focusing resources on best opportunities within Pfizer's existing portfolio, (2) broadening the geographic reach of its offerings especially in emerging Asian markets, and (3) developing partnerships to accelerate growth. Key priorities include optimizing top products like Lipitor, Lyrica, and Celebrex, investing in oncology and other disease areas, and capturing growth opportunities in established and emerging markets.
This document discusses how complementary technologies can help bridge academic research and industrial innovation. It provides examples of how the KU Leuven University uses enabling technology centers like its Center for Drug Design and Discovery and PharmAbs antibody center to translate biomedical research into new drugs, biomarkers, assays, and products. These centers help move research from basic discovery to valorization outcomes like patents, industrial contracts, spin-offs, and licensing agreements. One example described how KU Leuven used antibody assays to help optimize treatment for Crohn's disease patients losing response to Remicade therapy.
Mark Redmond has worked in various areas of innovation including genetically engineered vaccines, immunopharmaceuticals to control infection and disease, anti-inflammatory drugs, wound care products, diabetes diagnostics, and over 120 patented health technologies. He has designed manufacturing processes and plants, developed business strategies, international partnerships, and earned awards for his scientific and commercial achievements.
Best Practices, LLC is a research and consulting firm that provides benchmarking reports and advisory services to pharmaceutical, biotech, and medical device companies. It has nearly two decades of experience working with top companies in these industries. BPLLC's services include conducting research to identify best practices in areas like sales, product development, and medical affairs. It collects both quantitative and qualitative data through surveys and interviews to understand how industry leaders approach various challenges. BPLLC then analyzes the data and presents actionable recommendations and insights to help clients optimize their organizations and outperform competitors. Many of BPLLC's past clients report marked improvements after implementing the strategies and practices it identified.
Report summary for "U.S. Sales Communications Excellence: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications." Contact me for details on how to access the full report.
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...Best Practices
To ensure organizational health and competitiveness, companies must continually identify optimal resource levels for their operations. Best Practices conducted this study to identify the staffing and budgeting levels necessary to support effective Public Affairs functions in the U.S. In this study, data was broken into 6 Public Affairs functions: Government Affairs (State and Federal Government Relations and Public Policy), Corporate Communications – External, Corporate Communication – Internal, Product Communications, Corporate Social Responsibility, and Alliance Management.
This document summarizes Sweet Sensors' glucose monitoring technology that can detect a wide range of non-glucose targets at low concentrations, as well as next steps to validate customer needs, segmentation, and market accessibility. It also discusses following FDA regulations for in vitro diagnostics or looking at applications that don't require approval, and evaluating other options that provide immediate detection of targets like melamine in milk or bacteria in food.
G7 Diagnostics is launching SaphvidTM, a new product for early detection of pre-eclampsia, and has outlined their marketing plan to ensure sales and create a positive perspective. Their plan includes analyzing the market and customer needs, positioning SaphvidTM as reliable and easy-to-use, and implementing strategies like press releases, clinical studies, conferences and awareness campaigns. They will target obstetricians, midwives and pregnant women in the UK initially and look to expand globally by identifying international distributors and obtaining necessary regulatory approvals. The marketing budget is estimated to be over £153,000 over the next year.
Nerac is a global research and advisory firm that provides expert research and consulting services to companies developing innovative products and technologies. It offers services to support key processes in research and development, business development, marketing, regulatory affairs, intellectual property, and reimbursement. Nerac employs over 95 analysts with advanced degrees and specialized expertise. It works with over 1,500 clients worldwide each year to help accelerate critical decisions, identify opportunities, navigate regulatory requirements, and strengthen intellectual property strategies.
This document is a mini career portfolio describing the author's professional achievements and qualifications. It includes a brief bio, highlights of career achievements such as planning a successful regional conference and receiving an employee award, demonstrations of leadership abilities like writing a business plan and developing partnerships, and examples of competencies in areas like communication, customer satisfaction, and technology.
The document discusses new product development strategies and processes. It covers identifying opportunities, generating ideas, developing concepts, screening concepts, developing marketing plans, testing products, and commercializing products. Key aspects include establishing cross-functional teams, conducting market research like focus groups, and using stage gates to evaluate concepts and progress new products through the development cycle. The overall process moves from the fuzzy front end of identifying opportunities through developing and launching new products.
The document discusses new product development strategies and processes. It begins by outlining reasons for new product failures, such as overestimating market size. It then describes various NPD strategies including developing original products, acquisitions, and product improvements. The core of the document focuses on the multi-stage NPD process, from opportunity identification and concept development to testing, marketing planning, and commercialization. Cross-functional teams and market research methods like focus groups are also emphasized.
Similar to Evolution Of Controlled Release Technology (20)
2. What’s in the name and logo.?
AT A GLANCE
“Aizant” is derived from the name “Aizan”, Caribbean goddess of healing
Arrow head represents GROWTH
Bird in flight signifies FREEDOM
Four circular walls – four values
Innovation, People, Learning
and Quality
Blue arc – our POSITIVE attitude
Our logo – GLOBAL experience and standards
CONFIDENTIAL 2
3. Vision and Mission
AIZANT DRUG RESEARCH SOLUTIONS PVT LTD
So Little Done, So Much To Do - Cecil Rhodes
Aizant Vision
To be a global leader for science based integrated drug development solutions
Our Mission
Pursuit of excellence through science and technology
Agile team with open communication and honoring deliverables
Environmentally and socially responsible research
Aizant Core Values
Innovation
People
Learning
Quality
CONFIDENTIAL 3
4. Overview
Overview
AT A GLANCE
Established by individuals with global pharmaceutical industry experience
(USA/India/Europe/Australia)
No. of Employees: 290+ full time
Close to 90% of staff dedicated to pursuing career in R&D
16 Ph.D’s (current and pursuing), 3 physicians & 60 Master’s degree holders
Core competencies
◦ Dosage form development
◦ cGMP scale-up and clinical supplies
◦ Clinical Research
◦ Bioanalytical
CONFIDENTIAL 4
5. CONTENT
Overview
Technology Evolution
Opportunities
Market Potential
Current Scenario
Future Trends
QbD in Controlled Release Technology
Indian Scenario
5
6. OVERVIEW
Controlled Release Technology- What, Why & How ?
Delivery of drug at a predetermined rate for an extended period of time while
maintaining blood concentration within therapeutic limits .
Drug Delivery Technology
V
A
L
Enable
New Drug New Drug U
+
• NME
+
New DDS
E
Proven DDS
&
Enhance
R
Proven Drug Proven Drug
+ + I
• LCMs
New DDS Proven DDS S
K
6
7. OVERVIEW
Controlled Release Technology- What, Why & How ?
Meet Clinical Patent/Exclu
sivity Competitive
Reduce Side needs
advantage
Effect
Market
Optimize Pk
Scintific Strategic Penetration
Profile
New brand
Delivery by
Conventional route Improve New Patient
Compliance population
7
12. OPPORTUNITIES
Regulatory
FDA Approvals : NCE Vs Reformulation 1.NCE like status with minimal R&D
REFORMULATION NCE
77
expense (2% of NCE Research) .
75
73
69 2.Minimal regulatory risk ( Pk / PD
64
55 goals are well defined.
49 50
3.New indication accessed through
31
505 (b) 2 route increase increases
25 26
21
18 18
patient pool.
17 16
4.Low cost clinical study Clinical end
point – typically bioavailability &
2002 2003 2004 2005 2006 2007 2008 2009
non inferiority.
5.Time to approval ~ time to market
is short in comparison to NDA.
12
13. OPPORTUNITIES
Commercial & Strategic
Life cycle Management -Cardizem Story
$1,200.00
$1,000.00
Sales [In $ 000s]
$800.00
$600.00 Cardizem CO
$400.00 Cardizem SR
$200.00 Cardizem IR
$-
1988 1989 1990 1991 1992 1993 1994 1995 1996
Year
Cardizem hcl has been reformulated and launched twice to maintain and
enhance its market share in the same therapeutic segment and helped
Aventis to protect it’s block buster
13
15. Market Driver
MARKET POTENTIAL
R&D Spend Vs NME Approved Cost/NME
R&D
productivity
Sales Loss
due to
Patent expiry
Revenue Loss due to patent expiry
Global pharmaceutical companies are desperately looking at
15
alternative strategy to increase profitability
16. MARKET POTENTIAL
Key Statistics
Global Sales Of Drug Delivery Product [2007 – 2014] [In $ billion] Market Share –Dosage form
Oral, 52%
Liposomes, 2% Transdermal, 1
2%
Injectable, 8%
Pulmunory, 19
%
Nasal, 7%
Ocular &
Buccal, 1%
• Global pharmaceutical market size - $555.5 billion in 2006
• Drugs incorporating NDDS ~ $72 billion (~13%)
• NDDS market has a CAGR of ~15% v/s ~6% CAGR
• There are 700 NDDS companies with more than 1700technologies
• Worldwide NDDS market ten times Indian Pharma market
BCC Research http://www.bccresearch.com/report/drug-delivery-systems-phm006g.html
GBI Research
16
17. MARKET POTENTIAL
Key Statistics
Drug delivery project [1999 to 2004]
Growing drug delivery segment : Oral drug delivery systems
Preferred business model : JV/Partnership
17
18. CONTENT
Overview
Technology Evolution
Opportunities
Market Potential
Present Scenario
Future Trends
QbD in Controlled Release Technology
Indian Scenario
18
19. PRESENT SCENARIO
Oral delivery system - OROS Technology (ALZA corporation)
Products in market:
Sudafed 24
hours (Pseudoephedrine)
Volmax (Salbutamol
• Single layer tablet: Drug core (water soluble drug with or without excipients)
• Semi permeable membrane with a drilled orifice
• Water imbibitions by the core because of osmotic action results in drug
dissolution, which is released at a controlled rate through the orifice
19
20. PRESENT SCENARIO
Oral delivery system - Geomatrix® (SKY Parma)
Products in market:
Cordicant -uno®
Madopar-DR
Sular-ER
•This technology Controls amount, timing and location of release in body.
•Formulation with predictable and reproducible drug release profile.
• Controls rate of drug diffusion throughout release process, ensuring 100% release
20
21. PRESENT SCENARIO
Transdermal delivery system - MicroCor™ (Corium company)
• Has an array of microstructures that mechanically creates reversible “micro-pores” in the
outer skin barrier to facilitate transdermal delivery.
• Microstructures are integrated into a patch which contains both the drug and adhesive
• Drug candidates cross all major therapeutic areas
• The microstructure array is integrated into custom designed delivery systems for
painless administration of small and large molecular weight molecules through the skin.
• Delivery directly to the viable epidermis (20 to 200 µ)
http://www.coriumgroup.com
21
22. PRESENT SCENARIO
Parenteral
Depot or reservoir preparations
Parental administration prolonged by using insoluble
salts or suspensions in non-aqueous vehicles.
E.G Boldenone oil depo 1s a week inj, Testosterone
cypionate oil solution IM inj 1s a week.
Implants
Drug delivery systems implanted under skin from which
the drug is released slowly over a period of 1-5 years.
Norplant : Levonorgestrol subdermally implanted in
upper arm Provides contraceptive protection for ~5yrs.
Microspher
Small spheres made of any material and sized from
about .1-1000µm
E.G Risperdal consta
22
23. CONTENT
Overview
Technology Evolution
Opportunities
Market Potential
Current Scenario
Future Trends
QbD in Controlled Release Technology
Indian Scenario
23
24. FUTURE TREND
Polymer based delivery system
Hydrogels
•Polymers that swell without dissolving in an
aqueous environment releasing entrapped
drug
Ringcap Technology
•Tablet coated with water insoluble coat and
drug release is controlled based on count,
position & thickness of ring
Pulsincap Technology
•Capsule made of water soluble cap
•Drug is released when the hydro gel plug
swells and oozes the drug out of the shell
24
25. FUTURE TRENDS
Transdermal - Nano MAP
•For painless delivery of nanostructured large molecule drug or hormone.
•Delivery by topologically undulating patch.
•Proof of concept test for NanoMAPs has been demonstrated in rodent with
naoparticulate insulin
25
26. FUTURE TRENDS
Parenteral
Parenteral, especially biotechnology drugs, are ideal candidates for drug delivery technologies.
The success of next generation biotechnology molecules, including DNA-based drugs as well as
small interfering RNA molecules, depends on the effectiveness by which such molecules are
delivered to the desired site of action.
Needle less injection
Autoinjector
ProLease®, Medisorb® …..
These technologies enable delivery of complex macromolecules and small molecules to enhance drug
formulations, creating valuable medical and commercial benefits.
26
27. FUTURE TRENDS
Targeted Delivery System
Quantum dots
A quantum dot is a semiconductor nanostructure that confines the motion of
conduction band electrons, valence band holes, or exactions(bound pairs of
conduction band electrons and valence band holes) in all three spatial
directions. QDs can function as 'light beacons' by conjugating them to
chemotherapeutic drugs, such as doxorubicin. The QDs can be specifically
designed to fluoresce once the drug has been delivered and released
27
intracellularly.
28. FUTURE TRENDS
Targeted Delivery System
Folate Targeting
Folate targeting is a method utilized in biotechnology for drug delivery purposes.It
involves the attachment of the vitamin, folate(folic acid), to a molecule/drug to
form a "folateconjugate". Based on the natural high affinity of folate for the folate
receptor protein (FR), which is commonly expressed on the surface of many human
cancers, folate-drug conjugates also bind tightly to the FR and trigger cellular
28
uptake via endocytosis.
29. FUTURE TRENDS
Targeted Delivery System
Liposomes
These are vesicular concentric structures, range in size from a nanometer to several
micrometers, containing a phospholipids bilayer and are biocompatible, biodegradable
and no immunogenic.
E.G Allovectin-7 of Vical for delivery of antisense rNA
Oncolipin of Oncotheraputics Inc. for delivery of interlukins-1
Duanosome & Ambisome of Nextar Inc. for delivery of Doxorubicin & Amphotericin
29
30. Fabricated Delivery System
FUTURE TRENDS
The use of electronics opens up new possibilities in the era of drug delivery
•Active feedback system
•Implantable Device
•Programmable drug release profile
•Improved ease of use
•Great clinical and patient feedback
30
31. FUTURE TRENDS
Advance Delivery System
Molecular Gate
• pH sensitive gel
• Swells and deliver drug when pH
increases .
Nano robots
• Based on demand drug delivery
31
32. FUTURE TRENDS
Advance Delivery System
Nano robots
The device consist of a tiny nickel drum, attached to the ATP-powered biological
motor, which is coated with antibodies that adsorb the target molecules, whereupon
an electric field pulls the molecules to a storage chamber and holds them in place.
E.G Respirocytes : The artificial red blood cell
32
33. CONTENT
Overview
Technology Evolution
Opportunities
Market Potential
Current Scenario
Future Trends
QbD in Controlled Release Technology
Indian Scenario
33
34. QbD
Quality By Design
MOHEB NASR, FDA QUALITY INITIATIVES WORKSHOP, FEBRUARY 28, 2007
Empirical to mechanistic transition
34
35. QbD
Systematic Approach
• Target the product profile (TPP)
• Determine the critical quality attributes
(CQAs)
• Link input material attributes and process
parameters to CQAs and perform risk
assessment
• Develop a design space
• Design and implement a control strategy
• Manage product lifecycle, including
continual improvement
CHI-WAN CHEN AT 2007 AAPS ANNUAL MEETING, ROUND TABLE ON CHALLENGES AND OPPORTUNITIES FOR IMPLEMENTATION OF QUALITY BY DESIGN (QBD), SAN DIEGO, CA., NOV 13, 2007
35
37. INDIAN SCENARIO
Controlled Release Technology
Technology
Human resources
Regulatory
NDDS Scenario in India: Vital Role of Pharma Professionals-Pharmainfo.net
International journal of pharmatech research vol-2 (www.sphingsai.com) 37